Improvement in pH metrics in infants · GORD in infants
1 finding from 1 review
Endoscopic metrics ‐ not measured · GORD in infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in symptoms in infants · GORD in infants
1 finding from 1 review
Adverse events in infants ‐ not measured · GORD in infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in pH metrics in infants ‐ not measured · GORD in infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in endoscopic findings in infants ‐ not measured · GORD in infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in symptoms and signs in infants · GORD in infants
1 finding from 1 review
Clinical response at end of study (4 weeks) · people with inflammatory bowel disease
It is very uncertain whether vitamin D (all doses) changes clinical response at end of study (4 weeks) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Clinical relapse · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether any‐treatment‐dose vitamin D (greater than 400 IU/day) changes withdrawals due to adverse events compared with supplemental‐dose vitamin D (less than 400 IU/day) (very low certainty).
1 finding from 1 review
Clinical relapse · people with inflammatory bowel disease
Vitamin D (all doses) may leads to lower clinical relapse at end of study (26–52) weeks compared with placebo/no treatment (low certainty).
1 finding from 1 review
Quality of life at end of study (26 weeks) · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether vitamin D (all doses) changes withdrawals due to adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Clinical response · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with inflammatory bowel disease
High‐treatment‐dose vitamin D (greater than 1000 IU/day) showed no clear difference in clinical relapse at end of study (52 weeks) compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (low certainty).
1 finding from 1 review
Quality of life · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
1 finding from 1 review
Clinical response · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · Patients with active Crohn's disease
Infliximab 5–10 mg/kg may leads to higher clinical remission defined as CDAI < 150 at week 4 compared with placebo (low certainty).
1 finding from 1 review